Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangart initiates Hemospan Phase II study
The study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from chronic critical limb ischemia (CCLI),
The study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from chronic critical limb ischemia (CCLI),
JZP-8 is a novel drug delivery formulation incorporating clonazepam, a widely prescribed benzodiazepine. The product candidate is designed to be a fast-acting intranasal spray for the treatment of
The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties
The double blind, placebo-controlled, Phase II clinical trial is intended to enroll 150 mild to moderate AD patients who have an elevated levels of ‘free’ copper. Patients will
In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. Potent antiviral activity was demonstrated following four weeks of treatment with R7128 1500mg
The milestone payment was triggered when JCR Pharmaceuticals filed a clinical trial notice to the Pharmaceuticals and Medical Devices Agency in Japan to initiate a clinical trial in
Interim data available from 16 women and four men between the ages of 18 and 63 demonstrated that Plicera was generally well-tolerated at all doses evaluated. GCase (the
Cardica received the fourth and final milestone payment of $500,000 for the delivery of the Cook Vascular Closure Device (CVCD), an innovative automated system designed to close access
The round included lead investor Three Arch Partners and returning investors Versant Ventures and De Novo Ventures. Laurent Schaller, president and CEO of Benvenue Medical, said: “This financing
Patients in the initial 10 mcg/kg Maxy-G34 cohort met the safety criterion for duration of neutropenia (less than or equal to five days of severe neutropenia). No serious